The company previously laid off 265 workers at the facility in 2023 and 474 Bay Area-affiliated employees in 2020, saying it ...

EDITOR’S NOTE: An earlier version of this story misstated the reason behind the Genentech layoffs. We regret the error. (April 12, 2024) SAN FRANCISCO (KRON ...

The Bay Area has not only produced the world's biggest biotechnology firms—Genentech (S. San Francisco, CA), Chiron (Emeryville, CA), and Amgen (Thousand Oaks, CA)—it has also nurtured ...

Genentech, a South Bay-spawned global pharmaceutical firm, first made the joint announcement in March due to its Swiss parent company, the Roche Group, wanting to move its “large-scale ...

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...

Genentech, as well as other locations throughout the Bay Area and Internationally. She recently completed Artist Residencies at the Analog Research Laboratory at Facebook Headquarters, Menlo Park ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

The collaboration will perhaps serve as a boost for the San Francisco area after Pfizer ... Centre in Mission Bay recently. The group slated to work with Genentech is “staff, not students ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Genentech, a member of the Roche (RHHBY), announced ... for people with first-line diffuse large B-cell lymphoma, or DLBCL, an area that previously had little advancement in nearly two decades.

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...